1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 20 JULY 2015

CNS Drug News 20 JULY 2015

  • July 2015
  • -
  • Espicom Business Intelligence
  • -
  • 20 pages

Industry Trend Analysis - Newly Approved Rexulti Will Need To Be Differentiated From Predecessor Abilify
Industry Brief - Biotie Starts Tozadenant Phase III Study In PD
Industry Brief - Aurobindo Gains US Entacapone Approval
Industry Brief - Adamas Completes Recruitment Of ADS-5102 Phase III Study For PD-Associated LID
Industry Trend Analysis - Actavis' Grip On Namenda Market To Diminish
Industry Brief - CereSpir Obtains US Patent Covering Commercial Manufacture Of CSP-1103
Industry Brief - Cytokinetics Starts Phase III Trial Of Tirasemtiv In ALS
Industry Brief - FDA Grants ODD To C2N/AbbVie's C2N-8E12 For PSP
Industry Brief - EC Approves Vanda's Hetlioz For Non-24
Industry Brief - Ferrer Initiates Phase IIa Study Of Lorediplon In Insomnia
Industry Brief - SDP/Servier Partner On Latuda In Australia
Industry Brief - Saphris 2.5mg Tablets Available At Pharmacies Throughout US
Industry Trend Analysis - Abuse-Deterrent Formulations Will Increase Spend On Opioids
Industry Brief - Allergan To Acquire Worldwide Rights To Merck's CGRP Migraine Development Programme
Industry Brief - Teva Launches Almotriptan In US
Industry Brief - Fycompa Launched In UK For PGTC Seizures
Industry Trend Analysis - Resubmitted Sustol Will Be Growth Driver In CINV Drugs Market
Industry Brief - FDA Grants ODD To Newron's Sarizotan For Rett Syndrome
Industry Trend Analysis - Horizon Will Need To Raise Offer For Depomed
Industry Brief - Eisai To Transfer North Carolina Plant To Biogen
Industry Trend Analysis - Receptos Acquisition Will Enhance Celgene's Blockbuster Autoimmune Expectations
Industry Brief - Highland Forms US Commercial Subsidiary
Industry Brief - CNS Conferences - October 2015

Table Of Contents

CNS Drug News 20 JULY 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by GlobalData

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Europe Neurological Disorder Drugs Market: Overview This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.